CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

Core Insights - CervoMed is advancing the development of neflamapimod, targeting a Phase 3 trial in dementia with Lewy Bodies (DLB) set to begin in mid-2026 following discussions with regulatory authorities [1][3] Leadership Changes - Marco Verwijs, PhD, has been appointed as Executive Vice President of Technical Operations, bringing extensive experience in drug development and CMC functions from previous roles at notable biotech companies [2][3] Inducement Grants - On June 9, 2025, CervoMed granted Dr. Verwijs an option to purchase 54,000 shares of common stock at an exercise price of $7.74, with vesting over three years [4] Company Overview - CervoMed is focused on developing treatments for age-related neurologic disorders, with neflamapimod being an investigational small molecule aimed at treating synaptic dysfunction in DLB and other neurological disorders [5]